-
Sector Analysis
Non-Small Cell Lung Cancer (NSCLC) – Cell and Gene Therapies 15-Market Assessment and Forecast to 2031
Non-Small Cell Lung Cancer Market Report Overview The non-small cell lung cancer (NSCLC) market size for the 15 markets (15M) was $30.7 billion in 2021. This included both Cell & gene therapies (CGTs) and established/traditional therapies. Cell therapies, consisting mostly of tumor-infiltrating lymphocytes (TILs) and CAR-T cells, are the most-abundant modality type in the NSCLC CGT pipeline but fall far behind traditional therapies such as monoclonal antibodies and small molecules. The non-small cell lung cancer market research report includes an...
-
Product Insights
Non-Small Cell Lung Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Non-Small Cell Lung Cancer Pipeline Drugs Market Report Overview Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. NSCLC is a cancer (malignancy) that originates in the tissues of the lungs or the cells lining the airways. Symptoms of lung cancer usually occur in the later stages of the disease. The signs and symptoms include a persistent cough that may get worse over time, trouble breathing or shortness of breath, constant chest pain or discomfort, bloody...
-
Sector Analysis
Non-Small Cell Lung Cancer – Global Drug Forecast and Market Analysis to 2029
Non-small cell lung cancer (NSCLC) is currently the most common cancer in the world and is the leading cause of cancer mortality in men and women. Of total lung cancer incident cases, approximately 85% are the NSCLC subtype. NSCLC patients are usually diagnosed in the later stages of the disease, resulting in a poor prognosis. Since the last global market forecast (2015–2025), there have been significant changes in the treatment of patients with advanced disease, particularly in the metastatic setting....
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.